Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 18F-FDG PET/CT in ovarian cancer recurrence: Clinical impact, correlation with c...
Journal Information
Vol. 40. Issue 4.
Pages 207-213 (July - August 2021)
Share
Share
Download PDF
More article options
ePub
Visits
1
Vol. 40. Issue 4.
Pages 207-213 (July - August 2021)
Original Article
18F-FDG PET/CT in ovarian cancer recurrence: Clinical impact, correlation with ceCT and CA-125, and prognostic value
PET/CT con 18F-FDG en la recurrencia del cáncer de ovario: Impacto clínico, correlación con CT con contraste iv y CA-125, y valor pronóstico
Visits
...
Paloma García-Talaveraa,
Corresponding author
palomagtalavera@gmail.com

Corresponding author.
, Elena Alejob, Piedad Ariasc, Andrea Verdúc, Pilar Tamayoa, Felipe Gómez-Camineroa
a Servicio de Medicina Nuclear, Hospital Clínico Universitario de Salamanca, Spain
b Facultad de Medicina, Universidad de Salamanca, Spain
c Servicio de Radiodiagnóstico, Hospital Clínico Universitario de Salamanca, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (2)
Table 1. Results by cases and by lesions.
Table 2. ceCT vs PET/CT comparison.
Show moreShow less
Abstract
Aim

To evaluate 18F-FDG-PET/CT for suspected ovarian cancer relapse with negative/inconclusive conventional imaging, or restaging potentially resectable ovarian cancer relapse.

Material and methods

Thirty-six cases and 140 locations were studied. PET/CT, ceCT and serum CA-125 was conducted in all cases. Nineteen cases were requested for restaging, 17 for suspected relapse.

We compared ceCT and PET/CT, assessed by histopathology or radiological follow-up, calculating sensitivity (S) and positive predictive value (PPV) by cases and lesions.

We evaluated the correlation between size, number, uptake of the lesions and CA-125. We conducted survival analysis, using ROC curves to calculate the optimal cut-off of SUVmax for survival prediction.

We checked whether PET/CT modify the therapeutic attitude vs. conventional imaging.

Results

PET/CT and ceCT were concordant in 12 cases: 11 positives (30 lesions), all confirmed. There was 1 FN.

In the 24 non-concordant, PET/CT was positive in 19 (97 lesions); ceCT in 21 (59 lesions); 54% of the lesions were concordant.

Overall, PET/CT detected 127 lesions, with S=97% and PPV=100%. ceCT detected 89 lesions, with S=61% and PPV=90%.

No significant correlation was found between CA-125 and the other parameters. PET/CT detected 10 positive cases, with normal CA-125.

PET/CT modified therapeutic management in 15 cases.

Significant differences were found in survival with SUVmax=11.8

Conclusions

PET/CT plays an important role in ovarian cancer relapse, with sensitivity and PPV higher than ceCT, modified therapeutic management in up to 42% of cases, and could be a valuable tool for predicting survival.

Keywords:
18F-FDG PET/CT
Ovarian cancer recurrence
Prognostic value
Clinical impact
Resumen
Objetivo

Evaluar el 18F-FDG-PET/CT en la sospecha de recidiva del cáncer de ovario con pruebas de imagen negativas/no concluyentes, y en la re-estadificación de recurrencia potencialmente resecable.

Material y Métodos

Estudiamos 36 casos y 140 localizaciones. Se realizaron PET/CT, CT con contraste iv y CA-125 en todos los casos: re-estadificación (19), sospecha de recidiva (17).

Comparamos CT y PET/CT, valorados con histopatología y seguimiento radiológico, calculando sensibilidad y valour predictivo positivo (VPP) por casos y lesiones. Evaluamos la correlación entre tamaño, número y captación de las lesiones y el CA-125. Realizamos un análisis de supervivencia, utilizando curvas ROC para calcular el cut-off óptimo de SUVmax para predicción de supervivencia.

Comprobamos si el PET/CT modifica la actitud terapéutica vs imagen convencional.

Resultados

PET/CT y CT fueron concordantes en 12 casos: 11 positivos (39 lesiones), todos confirmados. Hubo 1 FN. En los 24 no concordantes, PET/CT fue positivo en 19 (97 lesiones); CT en 21 (59 lesiones); 54% de las lesiones fueron concordantes.

Globalmente, PET/CT detectó 127 lesiones (Sensibilidad=97% y VPP=100%) y CT 89 (Sensibilidad=61% y VPP=90%).

No se encontró correlación significativa entre CA-125 y los otros parámetros. El PET/CT detectó 10 casos positivos, con CA-125 normal. Modificó el manejo terapéutico en 15 casos. Se encontraron diferencias significativas en supervivencia (SUVmax=11.8).

Conclusiones

El PET/CT juega un importante papel en la recurrencia del cáncer de ovario, con sensibilidad y VPP mayores que el CT, modificó el manejo terapéutico en un 42% de casos y podría ser una herramienta útil para predicción de supervivencia.

Palabras clave:
PET/CT con 18F-FDG
Recurrencia cáncer de ovario
Valor pronóstico
Impacto clínico

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos